Cherie Stayner, PhD, is a biomedical researcher in the Dunedin School of Medicine, at the University of Otago, New Zealand. Her research has centred on the genetic basis and molecular mechanisms of polycystic kidney disease (PKD) in a number of different animal models, as well as in human autosomal dominant polycystic kidney disease (ADPKD). Studies initiated as a postdoctoral fellow at Brigham and Women’s Hospital/Harvard Medical School focused on genetic and therapeutic experiments in mouse models carrying a mutation in the Pkd1 gene, the most commonly mutated gene in human ADPKD. More recently, Dr Stayner and others have characterised the first large animal model for the recessive PKD disorder Meckel Syndrome, in a population of New Zealand sheep. Her previous work looking at rapamycin treatment in both mouse and sheep models of PKD has prompted an interest in tissue-targeted therapy options for slowing the progression of polycystic kidney disease, as well as investigations into the epigenetic changes associated with ADPKD.